Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Breast Cancer

Retrieve available abstracts of 87 articles:
HTML format
Text format



Single Articles


    April 2017
  1. YAMAMOTO S, Maeda N, Nagashima Y, Kubo H, et al
    A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Breast Cancer. 2017 Apr 24. doi: 10.1007/s12282-017-0779.
    PubMed     Text format     Abstract available


  2. KITAYAMA H, Kondo T, Sugiyama J, Kurimoto K, et al
    High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
    Breast Cancer. 2017 Apr 22. doi: 10.1007/s12282-017-0778.
    PubMed     Text format     Abstract available


  3. GHEYBI MK, Farrokhi S, Ravanbod MR, Ostovar A, et al
    The correlation of CD19 + CD24 + CD38 + B cells and other clinicopathological variables with the proportion of circulating Tregs in breast cancer patients.
    Breast Cancer. 2017 Apr 20. doi: 10.1007/s12282-017-0775.
    PubMed     Text format     Abstract available


  4. INARI H, Suganuma N, Kawachi K, Yoshida T, et al
    Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer.
    Breast Cancer. 2017 Apr 19. doi: 10.1007/s12282-017-0774.
    PubMed     Text format     Abstract available


  5. HANAMURA T, Hayashi SI
    Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
    Breast Cancer. 2017 Apr 7. doi: 10.1007/s12282-017-0772.
    PubMed     Text format     Abstract available


  6. MALEK-HOSSEINI Z, Jelodar S, Talei A, Ghaderi A, et al
    Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size.
    Breast Cancer. 2017 Apr 5. doi: 10.1007/s12282-017-0773.
    PubMed     Text format     Abstract available


  7. OGIYA A, Yamazaki K, Horii R, Shien T, et al
    Erratum to: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.
    Breast Cancer. 2017 Apr 4. doi: 10.1007/s12282-017-0771.
    PubMed     Text format    


    March 2017
  8. LIN WZ, Xu QN, Wang HB, Li XY, et al
    Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.
    Breast Cancer. 2017 Mar 21. doi: 10.1007/s12282-017-0770.
    PubMed     Text format     Abstract available


  9. ALTUNDAG K
    Robust predictive markers are needed for early detection of trastuzumab-related cardiac dysfunction in breast cancer.
    Breast Cancer. 2017 Mar 8. doi: 10.1007/s12282-017-0767.
    PubMed     Text format    


  10. GALLI G, Tessari A, Di Cosimo S
    Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of cross-sectional study design and biologic considerations about disease history.
    Breast Cancer. 2017 Mar 6. doi: 10.1007/s12282-017-0766.
    PubMed     Text format    


    February 2017
  11. KOGA C, Akiyoshi S, Ishida M, Nakamura Y, et al
    Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer.
    Breast Cancer. 2017 Feb 27. doi: 10.1007/s12282-017-0764.
    PubMed     Text format     Abstract available


  12. UOMORI T, Horimoto Y, Mogushi K, Matsuoka J, et al
    Relationship between alcohol metabolism and chemotherapy-induced emetic events in breast cancer patients.
    Breast Cancer. 2017 Feb 20. doi: 10.1007/s12282-017-0761.
    PubMed     Text format     Abstract available


  13. ALTUNDAG K
    Does longer disease-free interval affect the complete remission in metastatic breast cancer?
    Breast Cancer. 2017 Feb 16. doi: 10.1007/s12282-017-0762.
    PubMed     Text format    


    January 2017
  14. KOIKE Y, Ohta Y, Saitoh W, Yamashita T, et al
    Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Breast Cancer. 2017 Jan 31. doi: 10.1007/s12282-017-0757.
    PubMed     Text format     Abstract available


  15. LUO M, Ding L, Li Q, Yao H, et al
    miR-668 enhances the radioresistance of human breast cancer cell by targeting IkappaBalpha.
    Breast Cancer. 2017 Jan 30. doi: 10.1007/s12282-017-0756.
    PubMed     Text format     Abstract available


  16. INOUE M, Nakagomi H, Nakada H, Furuya K, et al
    Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Breast Cancer. 2017 Jan 20. doi: 10.1007/s12282-017-0753.
    PubMed     Text format     Abstract available


  17. ISHIKAWA T, Kaise H, Yamada K, Hosonaga M, et al
    Objection to postoperative radiation therapy in breast cancer with one to three lymph nodes involvements.
    Breast Cancer. 2017 Jan 9. doi: 10.1007/s12282-016-0749.
    PubMed     Text format     Abstract available


  18. TANAKA S, Suzuki K, Sakaguchi M
    The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.
    Breast Cancer. 2017 Jan 9. doi: 10.1007/s12282-017-0752.
    PubMed     Text format     Abstract available


  19. GALLI G, Tessari A, Porcu L, Bregni G, et al
    Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study.
    Breast Cancer. 2017 Jan 5. doi: 10.1007/s12282-017-0751.
    PubMed     Text format     Abstract available


  20. HALLAJIAN Z, Mahjoubi F, Nafissi N
    Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients.
    Breast Cancer. 2017 Jan 5. doi: 10.1007/s12282-016-0750.
    PubMed     Text format     Abstract available


  21. FUTAMURA M, Nagao Y, Ishihara K, Takeuchi M, et al
    Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
    Breast Cancer. 2017 Jan 3. doi: 10.1007/s12282-016-0748.
    PubMed     Text format     Abstract available


  22. SUGIE T, Toi M
    Antitumor immunity and advances in cancer immunotherapy.
    Breast Cancer. 2017;24:1-2.
    PubMed     Text format    


    December 2016
  23. PARK JH
    The effects of complex exercise on shoulder range of motion and pain for women with breast cancer-related lymphedema: a single-blind, randomized controlled trial.
    Breast Cancer. 2016 Dec 23. doi: 10.1007/s12282-016-0747.
    PubMed     Text format     Abstract available


    November 2016
  24. VELAEI K, Samadi N, Soltani S, Barazvan B, et al
    NFkappaBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  25. LI T, Liu Y, Xiao H, Xu G, et al
    Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  26. HOSSAIN A, Murshid GM, Zilani MN, Islam F, et al
    TP53 codon 72 polymorphism and breast cancer risk in Bangladeshi population.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  27. GUVELI H, Guveli ME, Sen F, Oflaz S, et al
    Effect of the childhood trauma on the adjustment to cancer in the patients with breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  28. IMAMURA T, Yamamoto-Ibusuki M, Sueta A, Kubo T, et al
    Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis.
    Breast Cancer. 2016;23:876-885.
    PubMed     Text format     Abstract available


  29. YAMASHITA H, Ogiya A, Shien T, Horimoto Y, et al
    Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Breast Cancer. 2016;23:830-843.
    PubMed     Text format     Abstract available


  30. SHIMO A, Tsugawa K, Tsuchiya S, Yoshie R, et al
    Oncologic outcomes and technical considerations of nipple-sparing mastectomies in breast cancer: experience of 425 cases from a single institution.
    Breast Cancer. 2016;23:851-860.
    PubMed     Text format     Abstract available


    October 2016
  31. MARUTHANILA VL, Elancheran R, Kunnumakkara AB, Kabilan S, et al
    Recent development of targeted approaches for the treatment of breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  32. TANE K, Egawa C, Takao S, Yamagami K, et al
    Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  33. TAN T, Zhang K, Chen W
    Erratum to: Genetic variants of ESR1 and SGSM3 are associated with the susceptibility of breast cancer in the Chinese population.
    Breast Cancer. 2016.
    PubMed     Text format    


  34. YANG J, Tan Q, Fu Q, Zhou Y, et al
    Gastrointestinal microbiome and breast cancer: correlations, mechanisms and potential clinical implications.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


    September 2016
  35. NAKADA H, Nakagomi H, Hirotsu Y, Amemiya K, et al
    A study of tumor heterogeneity in a case with breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  36. OGIYA A, Yamazaki K, Horii R, Shien T, et al
    Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  37. UEMATSU T
    Possible supplemental breast cancer screening modalities.
    Breast Cancer. 2016.
    PubMed     Text format    


    August 2016
  38. ZHANG X, Fan Y, Liu B, Qi X, et al
    Med19 promotes breast cancer cell proliferation by regulating CBFA2T3/HEB expression.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  39. IKEDA T, Sugie T, Shimizu A, Toi M, et al
    Patterns of clinical practice for sentinel lymph node biopsy in women with node-negative breast cancer: the results of a national survey in Japan.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  40. SAKAKIBARA J, Sakakibara M, Shiina N, Fujimori T, et al
    Expression of cell polarity protein scribble differently affects prognosis in primary tumor and lymph node metastasis of breast cancer patients.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  41. IMOTO S, Yamauchi C, Komoike Y, Tsugawa K, et al
    Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  42. HSIEH WC, Lin C, Chen DR, Yu WF, et al
    Genetic polymorphisms in APE1 Asp148Glu(rs3136820) as a modifier of the background levels of abasic sites in human leukocytes derived from breast cancer patients and controls.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  43. LI J, Ren J, Sun W
    Systematic review of ixabepilone for treating metastatic breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


    July 2016
  44. ANDRYSZAK P, Wilkosc M, Zurawski B, Izdebski P, et al
    Verbal fluency in breast cancer patients treated with chemotherapy.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  45. TAN T, Zhang K, Sun WC
    Genetic variants of ESR1 and SGSM3 are associated with the susceptibility of breast cancer in the Chinese population.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


    June 2016
  46. NAGATA T, Shimada Y, Sekine S, Moriyama M, et al
    KLF4 and NANOG are prognostic biomarkers for triple-negative breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  47. EICHLER M, Singer S, Janni W, Harbeck N, et al
    Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  48. UEMATSU T
    The need for supplemental breast cancer screening modalities: a perspective of population-based breast cancer screening programs in Japan.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  49. PORDELI M, Nakhjiri M, Safavi M, Ardestani SK, et al
    Anticancer effects of synthetic hexahydrobenzo [g]chromen-4-one derivatives on human breast cancer cell lines.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


    May 2016
  50. HONDA K, Takeshita K, Murotani K, Mitsuma A, et al
    Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  51. MORIYA T
    The current topics of surgical pathology of breast cancer in Japan.
    Breast Cancer. 2016.
    PubMed     Text format    


  52. KACZYNSKA A, Herman-Antosiewicz A
    Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  53. BURUGU S, Asleh-Aburaya K, Nielsen TO
    Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


    April 2016
  54. SKAANE P
    Breast cancer screening with digital breast tomosynthesis.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  55. VASSILIS K, Ioannis G, Anna Z, Christina A, et al
    A unique hypofractionated radiotherapy schedule with 51.3 Gy in 18 fractions three times per week for early breast cancer: outcomes including local control, acute and late skin toxicity.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  56. HARA A, Taira N, Mizoo T, Nishiyama K, et al
    N-acetyltransferase 2 polymorphism and breast cancer risk with smoking: a case control study in Japanese women.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  57. PARVIN S, Islam MS, Al-Mamun MM, Islam MS, et al
    Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  58. TOZAKI M, Kuroki Y, Kikuchi M, Kojima Y, et al
    The Japanese Breast Cancer Society clinical practice guidelines for screening and imaging diagnosis of breast cancer, 2015 edition.
    Breast Cancer. 2016.
    PubMed     Text format    


  59. NISHIMUKAI A, Higuchi T, Ozawa H, Yanai A, et al
    Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


    March 2016
  60. MEATTINI I, Guenzi M, Fozza A, Vidali C, et al
    Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  61. NOOSHINFAR E, Safaroghli-Azar A, Bashash D, Akbari ME, et al
    Melatonin, an inhibitory agent in breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  62. KUREBAYASHI J, Toyama T, Sumino S, Miyajima E, et al
    Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group compara
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  63. NAKANO Y, Noguchi M, Yokoi-Noguchi M, Ohno Y, et al
    The roles of F-FDG-PET/CT and US-guided FNAC in assessment of axillary nodal metastases in breast cancer patients.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  64. YOSHINAMI T, Yagi T, Okuno J, Kittaka N, et al
    Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  65. KOKKONEN K, Saarto T, Makinen T, Pohjola L, et al
    The functional capacity and quality of life of women with advanced breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  66. KOJIMA R, Okada E, Ukawa S, Mori M, et al
    Dietary patterns and breast cancer risk in a prospective Japanese study.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  67. TOKES T, Kajary K, Szentmartoni G, Lengyel Z, et al
    Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  68. KAWAGUCHI K, Suzuki E, Yamaguchi A, Yamamoto M, et al
    Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


    February 2016
  69. JINNO H, Inokuchi M, Ito T, Kitamura K, et al
    The Japanese Breast Cancer Society clinical practice guideline for surgical treatment of breast cancer, 2015 edition.
    Breast Cancer. 2016.
    PubMed     Text format    


  70. HORII R, Honma N, Ogiya A, Kozuka Y, et al
    The Japanese Breast Cancer Society clinical practice guidelines for pathological diagnosis of breast cancer, 2015 edition.
    Breast Cancer. 2016.
    PubMed     Text format    


  71. AIHARA T, Toyama T, Takahashi M, Yamamoto Y, et al
    The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition.
    Breast Cancer. 2016.
    PubMed     Text format    


  72. TANG S, Zhou F, Sun Y, Wei L, et al
    CEA in breast ductal secretions as a promising biomarker for the diagnosis of breast cancer: a systematic review and meta-analysis.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  73. YAMAUCHI C, Sekiguchi K, Nishioka A, Arahira S, et al
    The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2015 edition.
    Breast Cancer. 2016.
    PubMed     Text format    


  74. KUBA S, Ishida M, Oikawa M, Nakamura Y, et al
    Aromatase inhibitors with or without luteinizing hormone-releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  75. NAKATSUKASA K, Koyama H, Oouchi Y, Imanishi S, et al
    Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  76. TAIRA N, Arai M, Ikeda M, Iwasaki M, et al
    The Japanese breast cancer society clinical practice guidelines for epidemiology and prevention of breast cancer, 2015 edition.
    Breast Cancer. 2016.
    PubMed     Text format    


  77. INARI H, Shimizu S, Suganuma N, Yoshida T, et al
    A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  78. SATO K, Mizuno Y, Fuchikami H, Kato M, et al
    Impact of young age on local control after partial breast irradiation in Japanese patients with early stage breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


    January 2016
  79. SIDDIQUI S, Akhter N, Deo SV, Shukla NK, et al
    A study on promoter methylation of PTEN in sporadic breast cancer patients from North India.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  80. NAKATSUKASA K, Koyama H, Oouchi Y, Imanishi S, et al
    Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  81. NISHIMURA R, Okamoto N, Satou M, Kojima K, et al
    Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


    December 2015
  82. AKBARI ME, Kashani FL, Ahangari G, Pornour M, et al
    Erratum to: The effects of spiritual intervention and changes in dopamine receptor gene expression in breast cancer patients.
    Breast Cancer. 2015.
    PubMed     Text format    


  83. KATAYAMA Y, Motoki T, Watanabe S, Miho S, et al
    A very rare case of breast cancer in a female-to-male transsexual.
    Breast Cancer. 2015.
    PubMed     Text format     Abstract available


  84. PRAESTEGAARD C, Kjaer SK, Andersson M, Steding-Jensen M, et al
    Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort study.
    Breast Cancer. 2015.
    PubMed     Text format     Abstract available


  85. ENDO Y, Dong Y, Kondo N, Yoshimoto N, et al
    HER2 mutation status in Japanese HER2-positive breast cancer patients.
    Breast Cancer. 2015.
    PubMed     Text format     Abstract available


    November 2015
  86. AKBARI ME, Kashani FL, Ahangari G, Pornour M, et al
    The effects of spiritual intervention and changes in dopamine receptor gene expression in breast cancer patients.
    Breast Cancer. 2015.
    PubMed     Text format     Abstract available


  87. SAJI S, Kimura-Tsuchiya R, Sasaki E
    Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?
    Breast Cancer. 2015.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: